ArticleMolecular therapy oncolytics2022

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.

Christopher Aled Chamberlain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.